External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes

被引:9
|
作者
Hubacek, J
Galbraith, PD
Gao, M
Humphries, K
Graham, MM
Knudtson, ML
Ghali, WA
机构
[1] Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada
[2] APPROACH, Calgary, AB, Canada
[3] APPROACH, Edmonton, AB, Canada
[4] Univ Alberta, Dept Med, Edmonton, AB T6G 2M7, Canada
[5] British Columbia Cardiac Registries, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.ahj.2005.04.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The recently published Michigan outcome prediction model (MM) for inhospital mortality was developed and validated on a series of consecutive patients undergoing percutaneous coronary intervention (PCI). Our purpose was to externally validate the performance of the MM in 2 separate cohorts of patients with acute coronary syndrome (ACS) undergoing PCI in Canada. Methods A validation of the MM and development of an extended MM were performed on data describing 10050 patients from the APPROACH prospective cohort study between January 1995 and December 2000. Performance of both models was assessed on an external data set of 3259 PCI cases from the British Columbia Cardiac Registries. Only patients with a diagnosis of ACS were included in the study. Results The original MM predicted death rates ranging from 0.1% to 60.6%, but lacked accuracy to predict inhospital mortality as severity increased. The extended MM predicted death rates more widely from 0.0% to a high of 91.0% with better accuracy to predict inhospital death in patients with ACS undergoing PCI. The areas under the receiver operating characteristic curve for the MM and the extended MM on the external validation data set were 0.93. and 0.95, respectively. Conclusion The MM predicts death after PCI in patients with ACS and identifies a clear gradient of risk. However, the enhanced MM developed specifically for the subset of patients with ACS demonstrated better prediction and cross-validated performance. These prediction rules can be useful for risk-adjustment analyses and for prognostication for individual patients.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 50 条
  • [1] Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes
    Ndrepepa, Gjin
    Neumann, Franz-Josef
    Menichelli, Maurizio
    Richardt, Gert
    Cassese, Salvatore
    Xhepa, Erion
    Kufner, Sebastian
    Lahu, Shqipdona
    Aytekin, Alp
    Sager, Hendrik B.
    Joner, Michael
    Ibrahim, Tareq
    Mueller, Arne
    Fusaro, Massimiliano
    Hapfelmeier, Alexander
    Laugwitz, Karl-Ludwig
    Schunkert, Heribert
    Kastrati, Adnan
    Kasel, Markus
    CORONARY ARTERY DISEASE, 2022, 33 (03) : 213 - 221
  • [2] Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes
    Bates E.R.
    Current Cardiology Reports, 2001, 3 (5) : 348 - 354
  • [3] Recurrence rates of acute coronary syndromes in patients undergoing percutaneous coronary intervention
    Hansen, HH
    Aaroe, J
    Hjortshoej, S
    Ravkilde, J
    Rasmussen, K
    EUROPEAN HEART JOURNAL, 2003, 24 : 75 - 75
  • [4] Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Curran, MP
    Keating, GM
    BIODRUGS, 2006, 20 (01) : 63 - 65
  • [5] Very Elderly Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention
    Wong, Bernard
    Lee, Kyu-Hyun
    El-Jack, Seif
    HEART LUNG AND CIRCULATION, 2021, 30 (09): : 1337 - 1342
  • [6] Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention
    Monique P. Curran
    Gillian M. Keating
    BioDrugs, 2006, 20 : 63 - 65
  • [7] Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Validation of the Logistic Clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) Score
    Farooq, Vasim
    Vergouwe, Yvonne
    Genereux, Philippe
    Bourantas, Christos V.
    Palmerini, Tullio
    Caixeta, Adriano
    Garcia-Garcia, Hector M.
    Diletti, Roberto
    Morel, Marie-angele
    McAndrew, Thomas C.
    Kappetein, Arie Pieter
    Valgimigli, Marco
    Windecker, Stephan
    Dawkins, Keith D.
    Steyerberg, Ewout W.
    Serruys, Patrick W.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (07) : 737 - 745
  • [8] PREDICTION OF ACUTE CORONARY SYNDROMES BY PERCUTANEOUS CORONARY ANGIOSCOPY IN PATIENTS WITH STABLE ANGINA
    UCHIDA, Y
    NAKAMURA, F
    TOMARU, T
    MORITA, T
    OSHIMA, T
    SASAKI, T
    MORIZUKI, S
    HIROSE, J
    AMERICAN HEART JOURNAL, 1995, 130 (02) : 195 - 203
  • [9] Bivalirudin during percutaneous coronary intervention in acute coronary syndromes
    Laine, Marc
    Lemesle, Gilles
    Dabry, Thibaut
    Panagides, Vassili
    Peyrol, Michael
    Paganelli, Franck
    Bonello, Laurent
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (03) : 295 - 304
  • [10] Spotlight on eptifibatide in percutaneous coronary intervention and acute coronary syndromes
    Plosker, GL
    Ibbotson, T
    DISEASE MANAGEMENT & HEALTH OUTCOMES, 2004, 12 (03) : 207 - 210